加载中...

MedXY News - metformin

MedXY AI/MedXY News/Tag: metformin

MedXY News

EnglishTag

metformin

44 all articles · 20 / page

Ask MedXY AI

clinical trial immunotherapy type 2 diabetes heart failure obesity clinical trials atrial fibrillation Cardiology biomarkers oncology cardiovascular risk public health Hypertension critical care Alzheimer's disease artificial intelligence breast cancer nutrition diabetes cardiovascular disease Pediatrics chronic kidney disease

Latest news

Tag

Genetic Variant in CUBN Gene Identified as Key Risk Factor for Metformin-Induced Vitamin B12 Deficiency

Genetic Variant in CUBN Gene Identified as Key Risk Factor for Metformin-Induced Vitamin B12 Deficiency

Researchers have identified a genetic variant in the cubilin gene (CUBN, rs1801222) that significantly increases the risk of metformin-induced vitamin B12 deficiency, with carriers of the AA genotype experiencing deficiency up to twice as f

Section: Diabetes & EndocrinologyApr 18, 2026

Fluvoxamine Shows Promise for Treating Long COVID Fatigue: Results from Adaptive Randomized Trial

Fluvoxamine Shows Promise for Treating Long COVID Fatigue: Results from Adaptive Randomized Trial

A randomized trial of 399 adults with long COVID fatigue found that fluvoxamine significantly reduced fatigue severity at 60 and 90 days compared to placebo, while metformin showed no benefit. The study represents a potential breakthrough i

Section: Infectious Diseases

Apr 3, 2026

Metformin-Induced Blunting of Exercise-Mediated Vascular Improvements in Adults with Metabolic Risk

Metformin-Induced Blunting of Exercise-Mediated Vascular Improvements in Adults with Metabolic Risk

This report examines how metformin may interfere with exercise-induced improvements in vascular insulin sensitivity and aerobic fitness in adults at risk for metabolic syndrome.

Section: CardiologyMar 20, 2026

Metformin and Ursodeoxycholic Acid Fail to Improve Post-COVID Recovery: Insights from a Randomized Controlled Trial

Metformin and Ursodeoxycholic Acid Fail to Improve Post-COVID Recovery: Insights from a Randomized Controlled Trial

A randomized clinical trial indicates that neither metformin nor ursodeoxycholic acid (UDCA) significantly improves recovery from postacute sequelae of SARS-CoV-2 (PASC) compared to placebo, highlighting the ongoing challenge of finding eff

Section: Infectious DiseasesMar 14, 2026

Metformin Fails to Improve Walking Performance in Peripheral Artery Disease: Results of the PERMET Randomized Trial

Metformin Fails to Improve Walking Performance in Peripheral Artery Disease: Results of the PERMET Randomized Trial

The PERMET randomized clinical trial found that metformin did not improve the 6-minute walk distance or secondary walking outcomes in patients with peripheral artery disease without diabetes, suggesting no benefit for functional impairment

Section: CardiologyFeb 24, 2026

Challenging the Metformin Monopoly: Insights from the SMARTEST Trial on Early-Stage Type 2 Diabetes Management

Challenging the Metformin Monopoly: Insights from the SMARTEST Trial on Early-Stage Type 2 Diabetes Management

The SMARTEST trial investigates whether dapagliflozin should replace metformin as first-line therapy for early type 2 diabetes. Baseline data reveals a surprisingly high microvascular event rate, highlighting the urgent need for early organ

Section: Diabetes & EndocrinologyJan 22, 2026

Metformin Mitigates Betamethasone-Induced Glycemic Dysregulation and Reduces Neonatal Hypoglycemia: Insights from a Randomized Clinical Trial

Metformin Mitigates Betamethasone-Induced Glycemic Dysregulation and Reduces Neonatal Hypoglycemia: Insights from a Randomized Clinical Trial

A multicenter randomized trial demonstrates that prophylactic metformin administration after antenatal betamethasone significantly improves maternal glycemic control and halves the risk of neonatal hypoglycemia in preterm infants, offering

Section: Diabetes & EndocrinologyJan 17, 2026

Metformin Fails to Delay Progression on Active Surveillance for Low‑Risk Prostate Cancer — Unexpected Signal in Obese Men

Metformin Fails to Delay Progression on Active Surveillance for Low‑Risk Prostate Cancer — Unexpected Signal in Obese Men

The MAST phase III trial found no benefit of metformin (850 mg twice daily) versus placebo for delaying progression in men with low‑risk prostate cancer on active surveillance; a prespecified subgroup showed increased pathologic progression

Section: newsNov 23, 2025

Metformin Does Not Delay Progression on Active Surveillance for Low‑Risk Prostate Cancer — Unexpected Signal in Obesity

Metformin Does Not Delay Progression on Active Surveillance for Low‑Risk Prostate Cancer — Unexpected Signal in Obesity

A randomized phase III trial (MAST) found metformin did not prolong progression‑free survival in men on active surveillance for low‑risk prostate cancer; an exploratory subgroup showed increased pathologic progression in obese patients.

Section: newsNov 23, 2025

Metformin Triggers Ferroptosis in AML Through Lipid Remodeling: A Repurposing Opportunity for Metabolic Subtypes

Metformin Triggers Ferroptosis in AML Through Lipid Remodeling: A Repurposing Opportunity for Metabolic Subtypes

A new ex vivo study shows metformin induces ROS-driven ferroptosis in acute myeloid leukemia (AML), particularly in samples with altered lipid metabolism (IDH2, FLT3 mutations). Lipidomic remodeling, CD36-mediated fatty acid uptake, and DGA

Section: Hematology-OncologyNov 23, 2025

Can Preconception Metformin Improve Hyperemesis Gravidarum?

Can Preconception Metformin Improve Hyperemesis Gravidarum?

An observational MotherToBaby cohort found fewer hyperemesis gravidarum cases among women with preconception metformin exposure versus no exposure, but small numbers and wide confidence intervals limit conclusions. Nausea/vomiting frequency

Section: newsNov 18, 2025

Metformin Selectively Lowers Vitamin B12 but Not Other Vitamin Levels: Clinical Implications for Long-Term Therapy

Metformin Selectively Lowers Vitamin B12 but Not Other Vitamin Levels: Clinical Implications for Long-Term Therapy

A 200‑patient cross‑sectional study found metformin use tripled the odds of vitamin B12 deficiency without affecting vitamins A, B1, B6, B9, C or E, highlighting the need for targeted B12 monitoring in long‑term metformin therapy.

Section: Diabetes & EndocrinologyNov 18, 2025

Metformin in Metastatic Hormone-Sensitive Prostate Cancer Undergoing Androgen Deprivation Therapy: Insights from the STAMPEDE Phase 3 Trial and Contemporary Evidence

Metformin in Metastatic Hormone-Sensitive Prostate Cancer Undergoing Androgen Deprivation Therapy: Insights from the STAMPEDE Phase 3 Trial and Contemporary Evidence

Comprehensive review of metformin’s role in metastatic prostate cancer with ADT highlights STAMPEDE trial’s findings: no significant overall survival benefit but metabolic side-effect mitigation. Integration of other RCTs outlines nuanced e

Section: Clinical UpdatesNov 17, 2025

Metformin Did Not Prevent Metabolic Syndrome During ADT but Improved Weight, Waist and HbA1c: Findings from the PRIME Phase 3 Trial

Metformin Did Not Prevent Metabolic Syndrome During ADT but Improved Weight, Waist and HbA1c: Findings from the PRIME Phase 3 Trial

In the PRIME randomized phase 3 trial, metformin did not significantly reduce metabolic syndrome incidence in men starting androgen deprivation therapy, but produced modest, clinically relevant reductions in body weight, waist circumference

Section: Diabetes & EndocrinologyNov 17, 2025

Chiglitazar Added to Metformin Improves Glycaemia and Lipids in T2DM: Results from the RECAM Phase III Trial

Chiglitazar Added to Metformin Improves Glycaemia and Lipids in T2DM: Results from the RECAM Phase III Trial

In the RECAM randomized phase III trial, chiglitazar (32 mg and 48 mg) as add‑on to metformin produced clinically meaningful HbA1c reductions and favorable lipid changes versus placebo over 24 weeks, with a tolerable safety profile characte

Section: Diabetes & EndocrinologyNov 17, 2025

Liraglutide Plus Metformin in Overweight/Obese PCOS: Greater Metabolic and Hormonal Benefits Than Metformin Alone

Liraglutide Plus Metformin in Overweight/Obese PCOS: Greater Metabolic and Hormonal Benefits Than Metformin Alone

A 2025 meta-analysis of 19 RCTs (n=1657) found liraglutide combined with metformin improved glycaemia, insulin resistance, BMI, sex hormones and lipids versus metformin alone in overweight or obese women with PCOS; evidence certainty was lo

Section: Diabetes & EndocrinologyNov 17, 2025

Liraglutide Plus Metformin in Overweight/Obese PCOS: Greater Metabolic and Hormonal Benefits Than Metformin Alone

Liraglutide Plus Metformin in Overweight/Obese PCOS: Greater Metabolic and Hormonal Benefits Than Metformin Alone

A 2025 meta-analysis of 19 RCTs (n=1657) found liraglutide combined with metformin improved glycaemia, insulin resistance, BMI, sex hormones and lipids versus metformin alone in overweight or obese women with PCOS; evidence certainty was lo

Section: Diabetes & EndocrinologyNov 17, 2025

Metformin Moderately Reduces Antipsychotic-Related Weight Gain in Youth with Bipolar Spectrum Disorders: Large Pragmatic 24‑Month Trial Supports Clinical Use

Metformin Moderately Reduces Antipsychotic-Related Weight Gain in Youth with Bipolar Spectrum Disorders: Large Pragmatic 24‑Month Trial Supports Clinical Use

A 1,565‑participant pragmatic randomized trial shows metformin added to lifestyle counseling produced modest but statistically significant reductions in BMI Z-score at 6 and 24 months in overweight/obese children and adolescents with bipola

Section: newsNov 17, 2025

AI-Derived Body Composition Analysis Unveils Muscle Volume, Metformin-Associated Adipose Effects, and the Obesity Paradox in NSCLC: Clinical and Molecular Insights

AI-Derived Body Composition Analysis Unveils Muscle Volume, Metformin-Associated Adipose Effects, and the Obesity Paradox in NSCLC: Clinical and Molecular Insights

AI-driven analysis identifies muscle volume as a robust predictor of survival in NSCLC, highlights metformin-modulated adipose effects, and elucidates molecular links to the obesity paradox, informing personalized prognosis beyond BMI.

Section: Clinical UpdatesNov 17, 2025

Metformin Modestly Reduces Antipsychotic-Associated Weight Gain in Youth with Bipolar Spectrum Disorders — Large Pragmatic Trial Supports Consideration in Practice

Metformin Modestly Reduces Antipsychotic-Associated Weight Gain in Youth with Bipolar Spectrum Disorders — Large Pragmatic Trial Supports Consideration in Practice

A large, pragmatic randomized trial found that adjunctive metformin produced a modest but statistically significant reduction in BMI Z-score at 6 and 24 months among overweight and obese youth with bipolar spectrum disorders treated with se

Section: newsNov 17, 2025

Prev 1 2 3 Next